DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
10903 New Hampshire Ave, Bldg71, Rm 5054 Silver Spring, MD 20993-0002 (240)402-9160 orabioinspectionalcorrespondence@fda.hhs.gov	3/4/2024-3/12/2024* FEI NUMBER 3014752610

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Eric C. Moreau, Site Head

FIRM NAME	STREET ADDRESS
GlaxoSmithKline Biologicals	637 Rue Des Aulnois
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Saint-Amand-Les-Eaux, Nord, 59230 France	Manufacturer

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

OBSERVATION 1

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically,
Your firm failed to open a deviation for approximately 46 days after observing and failing to adequately document atypical cracks in (b) (4) (b) (4) mL glass vials used to (b) (4) Shingrix. Your firm's supplier request for investigation report from (b) (4) dated 3-24-23 revealed a weakness in the bottom of the glass vials that leads to breakage with increased stress from your manufacturing process. Your firm utilized (b) (4) lots of (b) (4) vials produced before 4-24-23 to manufacture approximately (b) (4) batches ((b) (4) vials) of Shingrix released to the US market . For example,

Raw Material ID	Filling Batch	Aseptic Period Batch	(b) (4) Date	Post Visual Inspection	Vial Quantity Delivered
(b) (4)	AVZVA387D	(b) (4)	(b) (4) 2022	JAN 2023	(b) (4)
(b) (4)	AVZVA392D	(b) (4)	(b) (4) 2022	FEB 2023	(b) (4)
(b) (4)	AVZVA368D	(b) (4)	(b) (4) 2022	OCT 2022	(b) (4)
(b) (4)	AVZVA368E	(b) (4)	(b) (4) 2022	NOV 2022	(b) (4)
(b) (4)	AVZVA387B	(b) (4)	(b) (4) 2022	JAN 2023	(b) (4)
(b) (4)	AVZVA387A	(b) (4)	(b) (4)	JAN 2023	(b) (4)

SEE REVERSE OF THIS PAGE

EMPLOYEE(S) SIGNATURE
Susan M Jackson, Investigator - Team Biologics
Latorie S Jones, Investigator - Team Biologics

X Susan M Jackson Investigator - Team Biologics Signed By: Susan M. Jackson -S Date Signed: 03-12-2024 14:09:12

DATE ISSUED
3/12/2024

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
10903 New Hampshire Ave, Bldg71, Rm 5054 Silver Spring, MD 20993-0002 (240)402-9160 orabioinspectionalcorrespondence@fda.hhs.gov	3/4/2024-3/12/2024* FEI NUMBER 3014752610

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Eric C. Moreau, Site Head

FIRM NAME	STREET ADDRESS
GlaxoSmithKline Biologicals	637 Rue Des Aulnois
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Saint-Amand-Les-Eaux, Nord, 59230 France	Manufacturer

			2022		
(b) (4)	AVZVA387C	(b) (4)	(b) (4) 2022	JAN 2023	(b) (4)
(b) (4)	AVZVA392B	(b) (4)	(b) (4) 2022	FEB 2023	(b) (4)
(b) (4)	AVZVA392C	(b) (4)	(b) (4) 2022	FEB 2023	(b) (4)
(b) (4)	AVZVA391A	(b) (4)	(b) (4) 2022	FEB 2023	(b) (4)
(b) (4)	AVZVA391B	(b) (4)	(b) (4) 2022	FEB 2023	(b) (4)
(b) (4)	AVZVA392A	(b) (4)	(b) (4) 2022	FEB 2023	(b) (4)
(b) (4)	AVZVA396F	(b) (4)	(b) (4) 2022	FEB 2023	(b) (4)
(b) (4)	AVZVA396D	(b) (4)	(b) (4) 2022	FEB 2023	(b) (4)

Additionally,
Your firm received complaints with glass defects, especially cracks and breaks in the bottom of the glass vial, which utilized Muller and Muller 3mL vials with known defect of weakness in the bottom of the glass vial. For example,

Investigation #	Defect Type	Short description	Investigation opened	Investigation closed	Priority	Conclusion	Batch Number
400010457	Broken vial	1 broken antigen vial in the box	6/23/2023	1/15/2024	(b) (4)	(b) (4)	AVZVA368A
400010485	Broken vial	One broken Shingrix antigen in new box	6/28/2023	12/21/2023	(b) (4)	(b) (4)	AVZVA368E
400011500	Broken	A powder	11/2/2023	2/2/2024	(b) (4)	(b) (4)	AVZVA391A

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
10903 New Hampshire Ave, Bldg71, Rm 5054 Silver Spring, MD 20993-0002 (240)402-9160 orabioinspectionalcorrespondence@fda.hhs.gov	3/4/2024-3/12/2024* FEI NUMBER 3014752610

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Eric C. Moreau, Site Head

FIRM NAME	STREET ADDRESS
GlaxoSmithKline Biologicals	637 Rue Des Aulnois
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Saint-Amand-Les-Eaux, Nord, 59230 France	Manufacturer

	vial	component vial broken					
(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)
400011981	Broken vial	Antigen vial broken at the bottom clean	1/2/2024	2/14/2024	(b) (4)	(b) (4)	AVZVA392A
400012086	Broken vial	After reconstitution, vial exploded	1/12/2024	2/7/2024	(b) (4)	(b) (4)	AVZVA396F
400012235	Broken vial	Bottom of the antigen broke off the vial	1/30/2024	2/27/2024	(b) (4)	(b) (4)	AVZVA392C
(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)
(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)	(b) (4)

OBSERVATION 2

Procedures for the cleaning and maintenance of equipment are deficient regarding inspection of the equipment for cleanliness immediately before use.

Specifically,
On 07 March 2024 during the walk through of the aseptic filling area in Building (b) (4) Lyo Line (b) (4) where US licensed Shingrix vaccine is filled, the (b) (4) covering of the vial (b) (4) was observed to have splinter-like cracks. The cracks were observed directly over the location where the vial enters the (b) (4) .

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE		DATE ISSUED
	Susan M Jackson, Investigator - Team Biologics Latorie S Jones, Investigator - Team Biologics	X Susan M Jackson Investigator - Team Biologics Signed By: Susan M. Jackson -S Date Signed: 03-12-2024 14:09:12	3/12/2024

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
10903 New Hampshire Ave, Bldg71, Rm 5054 Silver Spring, MD 20993-0002 (240)402-9160 orabioinspectionalcorrespondence@fda.hhs.gov	3/4/2024-3/12/2024* FEI NUMBER 3014752610

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Eric C. Moreau, Site Head	
FIRM NAME GlaxoSmithKline Biologicals	STREET ADDRESS 637 Rue Des Aulnois
CITY, STATE, ZIP CODE, COUNTRY Saint-Amand-Les-Eaux, Nord, 59230 France	TYPE ESTABLISHMENT INSPECTED Manufacturer

OBSERVATION 3

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

Specifically,
Your firm does not perform an (b) (4) inspection of your reserve/retain samples for Shingrix vaccine.

Adverse drug experiences which are both serious and unexpected have not been reported to FDA within 15 calenda days of initial receipt of the information by your firm.

Specifically,

A. A total of eighty-four (84) 15-Day Alert reports were reported late (after 15 days) for Shingrix Vaccine (BLA125614). Example of the 15-Day alert reports submitted late to the FDA include but are not limited to the following cases:

Case ID	Initial GSK Receipt Date	Initial Date Submitted to FDA	Number of Calendar Days Late
(b) (4)	(b) (4) 2023	(b) (4) 2024	357
(b) (4)	(b) (4) 2023	(b) (4) 2024	329
(b) (4)	(b) (4) 2023	(b) (4) 2023	30
(b) (4)	(b) (4) 2023	(b) (4) 2023	30
(b) (4)	(b) (4) 2023	(b) (4) 2023	96
(b) (4)	(b) (4) 2023	(b) (4) 2024	55

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
10903 New Hampshire Ave, Bldg71, Rm 5054 Silver Spring, MD 20993-0002 (240)402-9160 orabioinspectionalcorrespondence@fda.hhs.gov	3/4/2024-3/12/2024*
	FEI NUMBER 3014752610

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Eric C. Moreau, Site Head	
FIRM NAME GlaxoSmithKline Biologicals	STREET ADDRESS 637 Rue Des Aulnois
CITY, STATE, ZIP CODE, COUNTRY Saint-Amand-Les-Eaux, Nord, 59230 France	TYPE ESTABLISHMENT INSPECTED Manufacturer

B. Your firm failed to assign, initiated, and implemented corrective and preventative actions (CAPAs) at an appropriate time to prevent future reoccurrence of late 15-Day Alert reports.

***DATES OF INSPECTION**

3/04/2024(Mon), 3/05/2024(Tue), 3/06/2024(Wed), 3/07/2024(Thu), 3/08/2024(Fri), 3/11/2024(Mon), 3/12/2024(Tue)

X Latorie S Jones
Investigator - Team Biologics
Signed By: Latorie S. Jones -S
Date Signed: 03-12-2024 14:09:57

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE		DATE ISSUED
	Susan M Jackson, Investigator - Team Biologics Latorie S Jones, Investigator - Team Biologics	X Susan M Jackson Investigator - Team Biologics Signed By: Susan M. Jackson -S Date Signed: 03-12-2024 14:09:12	3/12/2024

The observations of objectionable conditions and practices listed on the front of this form are reported:

1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."